Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

Background Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. Th...

Full description

Bibliographic Details
Main Authors: Lisa Zimmer, Serigne Lo, Caroline Robert, John Haanen, Ines Pires da Silva, Reinhard Dummer, Michael Manos, Joanna Mangana, Marcus O Butler, Richard D Carvajal, Alon Vaisman, Christian Posch, F Stephen Hodi, Paola Queirolo, Axel Hauschild, Christian U Blank, Maria Grazia Vitale, Karijn P M Suijkerbuijk, Alexander M Menzies, Aljosja Rogiers, Chiara Tentori, Joseph M Grimes, Megan H Trager, Sharon Nahm, Peter Bowling, Neha Papneja, April A N Rose, Jessica S W Borgers, Severine Roy, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Samuel D Saibil, Michael Erdmann, Laura Pala, Ryan J Sullivan, Wilson H Miller Jr, Osama E Rahma, Paul C Lorigan
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/1/e001931.full

Internet

https://jitc.bmj.com/content/9/1/e001931.full

Similar Items